UK's Hemogenyx Pharmaceuticals H1 loss widens on share-based payments

By Reuters News


Overview

  • UK biopharma firm's H1 loss widened, driven by non-cash share-based payment charge

  • Company raised £5.6 mln in H1 to fund clinical development of lead CAR-T therapy

  • Operating costs fell yr/yr excluding share-based payments, reflecting manufacturing outsourcing savings


Outlook

  • Company prioritises dose escalation in adult trial and enrolment of first paediatric patients

  • Hemogenyx aims to complete technology transfer to Cellin and begin treating patients in Estonia


Result Drivers

  • SHARE-BASED PAYMENT CHARGE - Widened H1 loss was mainly attributed to a non-cash share-based payment expense from options granted

  • MANUFACTURING OUTSOURCING - Underlying operating costs fell after outsourcing HG-CT-1 manufacturing to Made Scientific


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

H1 Loss Per Share

GBP 1.02


Reuters Recommended Reads

  • Sept 25 - US FDA approves Mirum's drug for rare bone disorder

  • Sept 25 - ADARx Pharmaceuticals shares soar in Nasdaq debut after upsized IPO

  • Sept 25 - Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.